The Library
Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal Carcinoma
Tools
Leong, S. S., Wee, J., Rajan, S., Toh, C. K., Lim, W. T., Hee, Siew Wan, Tay, M. H., Poon, D. and Tan, E. H. (2008) Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal Carcinoma. Cancer, 113 (6). pp. 1332-1337. doi:10.1002/cncr.23687 ISSN 0008-543X.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1002/cncr.23687
Abstract
BACKGROUND.
Nasopharyngeal carcinoma (NPC) is a disease that is highly responsive to various chemotherapeutic agents. In the metastatic setting, 2-drug combination chemotherapy generally provides a response rate of 55% to 75%, and median survival of 10 to 12 months. The objective of the current study was to assess the efficacy of a 3-drug combination followed by maintenance treatment in patients with metastatic NPC.
METHODS.
Patients with metastatic NPC were treated with a combination of gemcitabine at a dose of 1000 mg/m2, paclitaxel at a dose of 70 mg/m2, and carboplatin at an area under the concentration-time-curve (AUC) of 2.5 on Days 1 and 8 every 21 days. Patients who achieved partial or complete response continued to receive weekly 5-fluorouracil at a dose of 450 mg/m2 and leucovorin at a dose of 30 mg/m2 for 48 weeks.
RESULTS.
Twenty-eight patients were recruited. Twenty-two (79%) patients had ≥2 sites of disease. Toxicities were mainly from bone marrow suppression, with 79% grade 3/4 neutropenia, 32% grade 3/4 anemia, and 29% grade 3/4 thrombocytopenia (according to the National Cancer Institute Common Toxicity Criteria). The overall response rate to the 3-drug regimen was 86%, with a complete response rate of 11%. The median duration of response was 8 months and the median overall survival was 22 months.
CONCLUSIONS.
This regimen of a 3-drug combination followed by maintenance is feasible and has demonstrated an encouraging response rate and overall survival.
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Statistics and Epidemiology Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
Journal or Publication Title: | Cancer | ||||
Publisher: | John Wiley & Sons, Inc. | ||||
ISSN: | 0008-543X | ||||
Official Date: | 2008 | ||||
Dates: |
|
||||
Volume: | 113 | ||||
Number: | 6 | ||||
Page Range: | pp. 1332-1337 | ||||
DOI: | 10.1002/cncr.23687 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Reuse Statement (publisher, data, author rights): | Cited By :23 Export Date: 5 March 2015 | ||||
Access rights to Published version: | Restricted or Subscription Access | ||||
Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |